Month: July 2020

US $10.3 million order is first grinder contract for MÁV FKG Kft-t, which manages all maintenance and renovation of the national railway networkHungary joins the UK, Germany, Sweden and Italy, all of which have been using Harsco Rail grinders for yearsCAMP HILL, Pa., July 24, 2020 (GLOBE NEWSWIRE) — Harsco Corporation (NYSE: HSC) announced today that its Rail division has signed a $10.3 million contract with MÁV FKG Kft-t to provide it with an EU 20-stone rail grinder. This is the first-ever grinder order by Hungarian Railways, which joins a long list of countries that have been using the efficient and reliable Harsco Rail grinders for years.Harsco Rail’s 20 stone grinder (RGH20C2), which removes surface defects on rails and re-profiles the rail head on both rails, is one of the most technologically advanced grinders working today....

VANCOUVER, British Columbia, July 24, 2020 (GLOBE NEWSWIRE) — Skyharbour  Resources Ltd. (TSX-V:SYH)  (OTCQB:SYHBF) (Frankfurt:SC1P) (the “Company”) is pleased to announce that its partner company Azincourt Energy Corp. (“Azincourt”) has announced a Summer Geophysical Target Generation Program at East Preston Uranium Project located 50 km southeast of Patterson Lake in the Western Athabasca Basin, northern Saskatchewan, Canada. Preston Uranium Project Map:http://skyharbourltd.com/_resources/maps/SYH-Patterson-Lake.pdfSkyharbour and Dixie Gold Inc. (“Dixie Gold”) entered into an Option Agreement (the “Agreement”) with Azincourt whereby Azincourt has an earn-in option to acquire a 70% working interest in a portion of the Preston Uranium Project known as the East Preston Property. Under the Agreement, Azincourt has issued common shares...

OKLAHOMA CITY, July 24, 2020 (GLOBE NEWSWIRE) — Gulfport Energy Corporation (NASDAQ: GPOR) (“Gulfport” or the “Company”) announced the date and time of its conference call to discuss financial and operational results for the second quarter of 2020.Gulfport will hold its second quarter 2020 earnings conference call on Wednesday, August 5, 2020 at 9:00 a.m. Central Time. Gulfport’s second quarter 2020 earnings are scheduled to be released after the market close on Tuesday, August 4, 2020.Interested parties may listen to the call via Gulfport’s website at www.gulfportenergy.com or by calling toll-free at 866-373-3408 or 412-902-1039 for international callers. A replay of the call will be available for two weeks at 877-660-6853 or 201-612-7415 for international callers. The replay passcode is 13707137. The webcast will also be...

SAN FRANCISCO, July 24, 2020 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the second quarter ended June 30, 2020, on Friday, July 31, 2020 after NASDAQ market close.UNITY will not conduct a conference call in conjunction with the financial results press release.About UNITYUNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby provide transformative benefit in age-related diseases, such as osteoarthritis, eye diseases, neurological diseases and pulmonary diseases. More information is available...

MONTERREY, Mexico, July 24, 2020 (GLOBE NEWSWIRE) — Arca Continental, S.A.B. de C.V. (BMV: AC*) (“Arca Continental” or “AC”), the second-largest Coca-Cola bottler in Latin America, announced its results for the second quarter and first half of 2020 (“2Q20” and “6M20”).Table 1: Financial Highlights 2Q20 HIGHLIGHTSNet Sales reached Ps. 42,945 million, up 2.3% when compared to 2Q19.EBITDA totaled Ps. 8,235 million, a margin of 19.2%, representing an increase of 1.8%.Net Income declined 17.1% to Ps. 2,335 million for a margin of 5.4%.6M20 HIGHLIGHTSNet Sales increased 3.7% to Ps. 81,837 million.EBITDA totaled Ps. 14,872 million, 3.5% higher than 2Q19 for a margin of 18.2%.Net Income grew 10.9% to Ps. 5,013 million for a margin of 6.1%.COMMENTS FROM THE CHIEF EXECUTIVE OFFICER“In one of the most challenging quarters in our company’s...

— Clinical Development Program of Filgotinib Demonstrated Durable Efficacy Balanced with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks —Foster City, Calif., and Mechelen, Belgium, July 24 2020, 14:10 CET; regulated information – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) announced today the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Jyseleca® (filgotinib 200 mg and 100 mg tablets), an investigational, once-daily, oral, selective JAK1 inhibitor for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). The CHMP positive opinion is a scientific recommendation...

— Klinisch ontwikkelingsprogramma van filgotinib laat duurzame werkzaamheid en een consistent veiligheidsprofiel zien bij reumatoïde artritis tot 52 weken —Foster City, Calif., & Mechelen, België, 24 juli 2020, 14:10 CET; gereglementeerde informatie – Gilead Sciences, Inc. (Nasdaq: GILD) en Galapagos NV (Euronext & Nasdaq: GLPG) kondigen vandaag aan dat de Commissie voor geneesmiddelen voor menselijk gebruik (CHMP) van het Europees Geneesmiddelenagentschap (EMA) een positief advies heeft uitgebracht voor Jyseleca® (filgotinib 200 mg en 100 mg tabletten), een experimentele eenmaal daagse, orale, selectieve JAK1 remmer voor de behandeling van volwassenen met matige tot ernstige reumatoïde artritis (RA, in de volksmond reuma) die eerder onvoldoende hebben gereageerd  op of intolerant zijn voor ziekte-modificerende anti-reumatische ...

GUADALAJARA, Mexico, July 24, 2020 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) reported its consolidated results for the second quarter ended June 30, 2020 (2Q20). Figures are unaudited and have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).COVID-19 ImpactDuring the second quarter of the year, the COVID-19 pandemic considerably affected the Company’s results, mainly with the decrease in international and domestic passenger traffic. Even though the Government of Mexico did not issue any flight restrictions during the quarter, during the months of April and May, activity for certain economic sectors did suffer restrictions. Other sectors, deemed essential,...

If approved, Adakveo would be the first targeted sickle cell disease therapy available for use in EuropeCHMP opinion supported by data showing Adakveo significantly reduced the rate of vaso-occlusive crises, with patients on Adakveo spending fewer days in hospitalVaso-occlusive crises are sudden, unpredictable, and associated with an increased risk of organ damage and mortality1Basel, July 24, 2020 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending conditional marketing authorization of Adakveo® (crizanlizumab) for the prevention of recurrent vaso-occlusive crises (VOCs), or pain crises, in patients with sickle cell disease aged 16 years and older. Adakveo can be given as an add-on therapy to hydroxyurea/hydroxycarbamide...

Disciplined network strategy, strong operational performance, and wireless customer growth2Q 2020 highlightsConsolidated:$1.13 in earnings per share (EPS), compared with $0.95 in 2Q 2019; adjusted EPS (non-GAAP), excluding special items, of $1.18, compared with $1.23 in 2Q 2019.Operating revenue decline of 5.1 percent from second-quarter 2019.First-half 2020 cash flow from operations of $23.6 billion, an increase of $7.7 billion from first-half 2019.Second-quarter 2020 total debt reduction of $4.9 billion, and net debt (non-GAAP) reduction of $5.7 billion.Consumer:Total revenue of $21.1 billion, a decrease of 4.0 percent year over year.72,000 retail postpaid net additions, including 97,000 phone net additions and 199,000 postpaid smartphone net additions.Total retail postpaid churn of 0.69 percent, and retail postpaid phone churn of 0.51...